Israel-Based Medical Cannabis Solutions Provider, Kanabo Research, has Signed an Agreement With Constance Therapeutics From the US

Tel Aviv, Israel (ots/PRNewswire) -

Israeli startup Kanabo Research (http://www.kanaboresearch.com/),
which develops clinical solutions for extraction and vaporization of
medical cannabis, announces it is entering an agreement with
Constance Therapeutics, a US-based medical cannabis extraction
company.

(Photo: https://mma.prnewswire.com/media/682136/Constance_Therapeu
tics_and_Kanabo_Research.jpg )

According to the agreement, both companies will operate in the EU
to establish a cannabis cultivation farm as well as manufacturing
capabilities of cannabis active compounds - THC and CBD - to be used
in an array of medical treatments and chronic ailments such as
insomnia, PTSD and chronic pain. Simultaneously, Constance
Therapeutics will market Kanabo Research's solutions in the US market
where Constance Therapeutics has been operating since 2008.

"We are happy to join hands with a medical cannabis market leader
like Constance Therapeutics which will allow us to strengthen our
presence in the American market," said Avihu Tamir, co-founder and
CEO of Kanabo Research. "At the same time, we are operating to locate
global opportunities in light of the fact that many countries are
asking to join the medical cannabis revolution. The move will allow
us to accelerate our manufacturing pace - especially important now
because of the delays in medical cannabis export approvals in Israel
- and will provide us with an excellent base for additional
operations in other markets, primarily European markets."

Kanabo Research has seen significant momentum in the last few
months. Recently, the company received initial approvals from
Israel's Ministry of Health to use cannabis with its proprietary
VapePod vaporizer. Similarly, the company has commenced pre-clinical
trials of Kanabo's proprietary formulations that focus on sleep
disorders and in the future for patients suffering from PTSD.

"Constance Therapeutics is excited to partner with Kanabo
Research. Kanabo is similarly focused on research and evidence-based
solutions in the cannabis space as we are at Constance Therapeutics,"
said Constance Finley, Founder and CEO of Constance Therapeutics.
"The standardization Constance Therapeutics pioneered in extracts,
Kanabo matches in its precision dosing hardware. This is a natural
fit and extends each company's expertise into new territories and
most importantly, offers emerging cannabis customers the most
innovative and enjoyable option."

About Kanabo Research

Israeli Startup Kanabo Research conducts research and development